While tissue biopsy is still irreplaceable in diagnosing tumor malignancy, we intend to investigate whether liquid biopsy could be conducted to detect EGFR-TKI resistance mechanisms in NSCLC patients and hopefully save patients from undue suffering. This evidence concerns the gene EGFR and non-small cell lung carcinoma.